Eliem Therapeutics Funding: $80M Raised, Series A (2021)
Eliem Therapeutics is based in Seattle. It has raised $80M in total funding. Latest round: Series A.
Eliem Therapeutics funding overview
Eliem Therapeutics is based in Seattle. Eliem Therapeutics has raised $80M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in July 2021. The round record for Eliem Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include RA Capital Management, Access Biotechnology, Intermediate Capital Group. 3 distinct backers are named across the disclosed rounds.
Eliem Therapeutics at a glance
Total raised
$80M
Latest round
Series A
Latest round date
July 2021
Headquarters
Seattle
Notable investors
RA Capital Management, Access Biotechnology, Intermediate Capital Group
Frequently asked about Eliem Therapeutics funding
How much has Eliem Therapeutics raised?
Eliem Therapeutics has raised $80M in total disclosed funding across the rounds on record.
Who has invested in Eliem Therapeutics?
RA Capital Management, Access Biotechnology, Intermediate Capital Group are named among the investors backing Eliem Therapeutics.
What was the latest Eliem Therapeutics funding round?
The most recent disclosed round is a Series A, announced in July 2021.
Where is Eliem Therapeutics based?
Eliem Therapeutics is based in Seattle.
When did Eliem Therapeutics last raise?
The last disclosed Eliem Therapeutics round closed in July 2021 at Series A.
Round data for Eliem Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Seattle and backer lists below.
